Compare Constellation Energy Corporation (CEG) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs McKesson Corporation — how do they compare? Constellation Energy Corporation trades at $278.92 (market cap $98.63B), while McKesson Corporation trades at $878 (market cap $105.14B). The key difference: Constellation Energy Corporation and McKesson Corporation are close in size by market cap, and Constellation Energy Corporation pays the higher dividend (0.61%). Which is the better fit depends on your goals.
| CEG | MCK | |
|---|---|---|
Market Cap | $98.63B | $105.14B |
Sector | Energy | Health |
52-Week High | $403.95 | $995.69 |
52-Week Low | $236.50 | $659.01 |
Enterprise Value | $122.63B | $111.67B |
Dividend Yield | 0.61% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CEG trades at $278.68, up 3.05% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and Calpine integration. Revenue growth is robust, with 2026 projections at $31.3B, and profitability metrics like ROE of 15.26% highlight efficient capital use.
The stock offers upside to the consensus price target of $332.13, with 70% of analysts rating it Buy. Key risks include execution of growth initiatives and market volatility, but strong cash flow and strategic positioning in AI-driven power demand support a positive outlook for investors.
McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.
MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
